Advertisement

Surgical Endoscopy

, Volume 32, Issue 3, pp 1470–1477 | Cite as

Laparoscopic liver resection for metastatic melanoma

  • Davit L. Aghayan
  • Airazat M. Kazaryan
  • Åsmund Avdem Fretland
  • Mushegh A. Sahakyan
  • Bård I. Røsok
  • Bjørn Atle Bjørnbeth
  • Bjørn Edwin
Article

Abstract

Background

Stage IV metastatic melanoma carries a poor prognosis. In the case of melanoma liver metastasis (MLM), surgical resection may improve survival and represents a therapeutic option, with varying levels of success. Laparoscopic liver resection (LLR) for metastatic melanoma is poorly studied. The aim of this study was to analyze the outcomes of LLR in patients with MLM.

Materials and methods

Between April 2000 and August 2013, 11 (1 cutaneous, 9 ocular and 1 unknown primary) patients underwent LLR for MLM at Oslo University Hospital—Rikshospitalet and 13 procedures in total were carried out. Perioperative and oncologic outcomes were analyzed. Postoperative morbidity was classified using the Accordion classification. Kaplan–Meier method was used for survival analysis.

Results

A total of 23 liver specimens were resected. The median operative time was 137 (65–470) min, while the median blood loss was less than 50 (<50–900) ml. No intraoperative unfavorable incidents and 30‐day mortality occurred. Median follow-up was 33 (9–92) months. Ten patients (91%) developed recurrence within a median of 5 months (2–18 months) and two patients underwent repeat LLR for recurrent liver metastases. One-, three-, and five-year overall survival rates were 82, 45 and 9%, respectively. The median overall survival was 30 (9–92) months.

Conclusion

Perioperative morbidity and long-term survival after LLR for MLM seems to be comparable to open liver resection. Thus, LLR may be preferred over open liver resection due to the well-known advantages of laparoscopy, such as reduced pain and improved possibility for repeated resections.

Keywords

Laparoscopic liver resection Melanoma Liver metastases Survival 

Notes

Compliance with ethical standards

Disclosures

Davit L. Aghayan, Airazat M. Kazaryan, Åsmund Avdem Fretland, Mushegh A. Sahakyan, Bård I. Røsok, Bjørn Atle Bjørnbeth, and Bjørn Edwin have no conflicts of interest or financial ties to disclose.

References

  1. 1.
    Patel JK et al (1978) Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg 135(6):807–810CrossRefPubMedGoogle Scholar
  2. 2.
    Cohn-Cedermark G et al (1999) Metastatic patterns, clinical outcome, and malignant phenotype in malignant cutaneous melanoma. Acta Oncol 38(5):549–557CrossRefPubMedGoogle Scholar
  3. 3.
    Leiter U et al (2004) The natural course of cutaneous melanoma. J Surg Oncol 86(4):172–178CrossRefPubMedGoogle Scholar
  4. 4.
    Albert DM, Ryan LM, Borden EC (1996) Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch Ophthalmol 114(1):107–108CrossRefPubMedGoogle Scholar
  5. 5.
    Balch CM et al (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19(16):3622–3634CrossRefPubMedGoogle Scholar
  6. 6.
    Aoyama T et al (2000) Protracted survival after resection of metastatic uveal melanoma. Cancer 89(7):1561–1568CrossRefPubMedGoogle Scholar
  7. 7.
    Derek E et al (2013) Combined surgical resection and radiofrequency ablation as treatment for metastatic ocular melanoma. Surg Today 43(4):367–371CrossRefPubMedGoogle Scholar
  8. 8.
    Mariani P et al (2009) Surgical management of liver metastases from uveal melanoma: 16 years’ experience at the Institut Curie. Eur J Surg Oncol 35(11):1192–1197CrossRefPubMedGoogle Scholar
  9. 9.
    Salmon RJ et al (1998) Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy. Eur J Surg Oncol 24(2):127–130CrossRefPubMedGoogle Scholar
  10. 10.
    Bedikian AY et al (1995) Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 76(9):1665–1670CrossRefPubMedGoogle Scholar
  11. 11.
    Pawlik TM et al (2006) Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol 13(5):712–720CrossRefPubMedGoogle Scholar
  12. 12.
    Doussot A et al (2015) Liver resection and ablation for metastatic melanoma: a single center experience. J Surg Oncol 111(8):962–968CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Schelhorn J et al (2015) A single-center experience in radioembolization as salvage therapy of hepatic metastases of uveal melanoma. Acta Radiol Open 4(4):2047981615570417PubMedPubMedCentralGoogle Scholar
  14. 14.
    Faries MB et al (2014) A 20-year experience of hepatic resection for melanoma: is there an expanding role? J Am Coll Surg 219(1):62–68CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Alvarez-Downing MM et al (2012) Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma. World J Surg Oncol 10:113CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Olofsson R et al (2014) Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial. Trials 15:317CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Hameed AM et al (2014) Hepatic resection for metastatic melanoma: a systematic review. Melanoma Res 24(1):1–10CrossRefPubMedGoogle Scholar
  18. 18.
    Gomez D et al (2014) The Liverpool uveal melanoma liver metastases pathway: outcome following liver resection. J Surg Oncol 109(6):542–547CrossRefPubMedGoogle Scholar
  19. 19.
    Ryu SW et al (2013) Liver resection for metastatic melanoma: equivalent survival for cutaneous and ocular primaries. J Surg Oncol 108(2):129–135CrossRefPubMedGoogle Scholar
  20. 20.
    Ollila DW, Gleisner AL, Hsueh EC (2011) Rationale for complete metastasectomy in patients with stage IV metastatic melanoma. J Surg Oncol 104(4):420–424CrossRefPubMedGoogle Scholar
  21. 21.
    Edwin B, Nordin A, Kazaryan AM (2011) Laparoscopic liver surgery: new frontiers. Scand J Surg 100(1):54–65CrossRefPubMedGoogle Scholar
  22. 22.
    Kazaryan AM et al (2010) Laparoscopic resection of colorectal liver metastases: surgical and long-term oncologic outcome. Ann Surg 252(6):1005–1012CrossRefPubMedGoogle Scholar
  23. 23.
    Kazaryan AM et al (2010) Laparoscopic liver resection for malignant and benign lesions: ten-year Norwegian single-center experience. Arch Surg 145(1):34–40CrossRefPubMedGoogle Scholar
  24. 24.
    Wakabayashi G et al (2015) Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka. Ann Surg 261(4):619–629PubMedGoogle Scholar
  25. 25.
    Akyuz M et al (2016) Laparoscopic management of liver metastases from uveal melanoma. Surg Endosc 30(6):2567–2571CrossRefPubMedGoogle Scholar
  26. 26.
    Edwin B et al (2001) Liver tumors and minimally invasive surgery: a feasibility study. J Laparoendosc Adv Surg Tech A 11(3):133–139CrossRefPubMedGoogle Scholar
  27. 27.
    Mala T et al (2005) Laparoscopic liver resection: experience of 53 procedures at a single center. J Hepatobiliary Pancreat Surg 12(4):298–303CrossRefPubMedGoogle Scholar
  28. 28.
    Strasberg SM, Linehan DC, Hawkins WG (2009) The accordion severity grading system of surgical complications. Ann Surg 250(2):177–186CrossRefPubMedGoogle Scholar
  29. 29.
    Porembka MR et al (2010) Quantitative weighting of postoperative complications based on the accordion severity grading system: demonstration of potential impact using the american college of surgeons national surgical quality improvement program. J Am Coll Surg 210(3):286–298CrossRefPubMedGoogle Scholar
  30. 30.
    Satava RM (2005) Identification and reduction of surgical error using simulation. Minim Invasive Ther Allied Technol 14(4):257–261CrossRefPubMedGoogle Scholar
  31. 31.
    Kazaryan AM, Rosok BI, Edwin B (2013) Morbidity assessment in surgery: refinement proposal based on a concept of perioperative adverse events. ISRN Surg 2013:625093CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Reddy SK, Tsung A, Geller DA (2011) Laparoscopic liver resection. World J Surg 35(7):1478–1486CrossRefPubMedGoogle Scholar
  33. 33.
    O’Rourke TR et al (2008) Long-term results of liver resection for non-colorectal, non-neuroendocrine metastases. Ann Surg Oncol 15(1):207–218CrossRefPubMedGoogle Scholar
  34. 34.
    Takemura N et al (2013) Long-term results of hepatic resection for non-colorectal, non-neuroendocrine liver metastasis. Hepatogastroenterology 60(127):1705–1712PubMedGoogle Scholar
  35. 35.
    Frenkel S et al (2009) Long-term survival of uveal melanoma patients after surgery for liver metastases. Br J Ophthalmol 93(8):1042–1046CrossRefPubMedGoogle Scholar
  36. 36.
    Rose DM et al (2001) Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch Surg 136(8):950–955CrossRefPubMedGoogle Scholar
  37. 37.
    Kodjikian L, Grange JD, Rivoire M (2005) Prolonged survival after resection of liver metastases from uveal melanoma and intra-arterial chemotherapy. Graefes Arch Clin Exp Ophthalmol 243(6):622–624CrossRefPubMedGoogle Scholar
  38. 38.
    Postriganova N et al (2014) Margin status after laparoscopic resection of colorectal liver metastases: does a narrow resection margin have an influence on survival and local recurrence? HPB (Oxford) 16(9):822–829CrossRefGoogle Scholar
  39. 39.
    Montalti R et al (2015) Impact of surgical margins on overall and recurrence-free survival in parenchymal-sparing laparoscopic liver resections of colorectal metastases. Surg Endosc 29(9):2736–2747CrossRefPubMedGoogle Scholar
  40. 40.
    Kolandjian NA et al (2013) Delayed systemic recurrence of uveal melanoma. Am J Clin Oncol 36(5):443–449CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Li Y, McClay EF (2002) Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol 29(5):413–426CrossRefPubMedGoogle Scholar
  42. 42.
    Rivoire M et al (2005) Treatment of liver metastases from uveal melanoma. Ann Surg Oncol 12(6):422–428CrossRefPubMedGoogle Scholar
  43. 43.
    Lui P et al (2007) Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat Rev 33(8):665–680CrossRefPubMedGoogle Scholar
  44. 44.
    Hamm C et al (2008) Biochemotherapy for the treatment of metastatic malignant melanoma: a systematic review. Cancer Treat Rev 34(2):145–156CrossRefPubMedGoogle Scholar
  45. 45.
    Jilaveanu LB, Aziz SA, Kluger HM (2009) Chemotherapy and biologic therapies for melanoma: do they work? Clin Dermatol 27(6):614–625CrossRefPubMedGoogle Scholar
  46. 46.
    Dillman RO et al (2012) Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma? Cancer Biother Radiopharm 27(6):337–343CrossRefPubMedGoogle Scholar
  47. 47.
    Coit DG et al (2013) Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 11(4):395–407CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Davit L. Aghayan
    • 1
    • 4
  • Airazat M. Kazaryan
    • 1
    • 3
  • Åsmund Avdem Fretland
    • 1
    • 2
    • 4
  • Mushegh A. Sahakyan
    • 1
    • 4
  • Bård I. Røsok
    • 2
  • Bjørn Atle Bjørnbeth
    • 2
  • Bjørn Edwin
    • 1
    • 2
    • 4
  1. 1.The Intervention CentreOslo University Hospital – RikshospitaletOsloNorway
  2. 2.Department of Hepato-Pancreato-Biliary SurgeryOslo University HospitalOsloNorway
  3. 3.Department of Gastrointestinal SurgeryAkershus University HospitalLørenskogNorway
  4. 4.Faculty of Medicine, Institute of Clinical MedicineUniversity of OsloOsloNorway

Personalised recommendations